Rewriting the infertility script.
The journey to parenthood, often filled with hope, is for millions of women marked by emotional distress, high costs, and invasive treatments. On average, it takes a woman three years to realize she needs fertility treatment—three critical years during which fertility declines. With the high cost of IVF, which can exceed $15,000 per cycle, many women face financial strain alongside the emotional burden. As more women choose to start families later in life due to career and personal factors, biological challenges like declining egg reserves make conception even harder.
Microgenesis aims to solve this problem. After over 15 years of research in immunology and reproductive health, the founders recognized that many infertility struggles stem from underlying inflammatory conditions often overlooked by conventional treatments. Their innovative, non-invasive approach focuses on restoring balance to the gut microbiome, addressing the root cause of inflammation and improving reproductive health, offering a more affordable and timely alternative to IVF.
Tackling the root cause of infertility
Microgenesis is revolutionizing fertility treatment with a personalized, non-invasive solution that enhances women’s chances of conception through cutting-edge science and deep learning algorithms. Central to their innovation is microRNA technology, which analyzes the gut microbiome and its effects on reproductive health. Microgenesis has developed a system to identify 98 unique inflammatory profiles influenced by biological factors, geography, nutrition, and lifestyle.
Deep learning algorithms play a crucial role in this process by analyzing large data sets to recognize patterns in microbiome and inflammatory responses, predicting how various factors can affect fertility outcomes. This approach allows for tailored treatment plans that consider a woman’s biology and specific environment.
The results speak for themselves: Microgenesis has treated over 700 women and is nearing the milestone of 500 babies born, showcasing the effectiveness of their method in helping women conceive naturally. This innovative combination of science, technology, and personalized care positions Microgenesis as a pioneer in fertility treatment, making parenthood more accessible and achievable for women everywhere.
Expanding proof of concepts to new regions
Microgenesis secured its first round of investment from Happiness Capital at the beginning of 2021. Since then, Happiness Capital has provided ongoing support, connecting Microgenesis with international markets and helping the company with entry into Asia.
With the support of Happiness Capital, Microgenesis has successfully expanded its operations to Spain, Argentina, and the United States, and is now preparing to enter the Chinese market to replicate its proof of concept. Happiness Capital has been a vital partner in this journey, providing invaluable strategic advice, global connections, and the flexibility to innovate, helping Microgenesis scale and thrive.
Forward-looking fertility solutions
Looking ahead, Microgenesis long-term goal is to shift from being a solution for women who have already tried IVF to becoming a preventive option for women seeking to preserve their fertility potential through personalized care.
With their deep-learning algorithm, which analyzes geographic, nutritional, and lifestyle factors, Microgenesis is poised to lead the way in personalized fertility treatment. Their mission is not just to help women conceive, but to empower them to take control of their overall health through science-backed, personalized solutions.
